In 2005, a double-blind clinical trial was performed to assess the effect of intrathecal administration of IGF-1 in 9 patients with ALS, revealing a positive effect in motor functions without any variations in vital capacity (Nagano et al., 2005). This evidence concerns the gene IGF1 and amyotrophic lateral sclerosis.